Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498965 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL8003223 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28522527 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL247769 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28515810 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL25342942 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL9460784 | 0.93 | NAAA (0.52) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL28260707 | 0.91 | NAAA (0.46) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL11267960 | 0.87 | NAAA (0.46) | NAAAEPHX1TSHRMEN1MAPT | |
| SCHEMBL28823876 | 0.85 | ALDH1A1 (0.47) | NAAAEPHX1TSHRHCAR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968248-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | Nal Pharmaceuticals Ltd. (CN) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152454-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (CN) | 2014-09-25 | — | — | WO | claimed |
| US-20140271866-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (HK) | 2014-09-18 | — | — | US | claimed |
| EP-2589379-B1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL | NAL PHARMACEUTICAL GROUP LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-9693970-B2 | Transdermal drug delivery system containing donepezil | NAL PHARMACEUTICALS GROUP LIMITED (HK) | 2017-07-04 | — | — | US | disclosed |
| US-9290470-B2 | Process for the preparation of karanja oil-based epoxy and acyloxy compounds as lubricant basestocks | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-03-22 | — | — | US | disclosed |
| EP-2968248-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | Nal Pharmaceuticals Ltd. (CN) | 2016-01-20 | — | — | EP | disclosed |
| US-20150352058-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL | NAL PHARMACEUTICALS LTD. (HK) | 2015-12-10 | — | — | US | disclosed |
| US-9155711-B2 | Transdermal drug delivery system containing donepezil | NAL PHARMACEUTICALS, LTD. (CN) | 2015-10-13 | — | — | US | disclosed |
| US-20150191441-A1 | PROCESS FOR THE PREPARATION OF KARANJA OIL-BASED EPOXY AND ACYLOXY COMPOUNDS AS LUBRICANT BASESTOCKS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-07-09 | — | — | US | disclosed |
| US-20140370076-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL | NAL PHARMACEUTICAL GROUP LIMITED (HK) | 2014-12-18 | — | — | US | disclosed |
| CN-103096882-B | Transdermal preparation containing donepezil | NAL PHARMACEUTICALS LTD | 2014-06-11 | — | — | CN | disclosed |
| WO-2014009972-A1 | A PROCESS FOR THE PREPARATION OF KARANJA OIL-BASED EPOXY AND ACYLOXY COMPOUNDS AS LUBRICANT BASESTOCKS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-01-16 | — | — | WO | disclosed |
| EP-2589379-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL | Nal Pharmaceuticals Ltd. (CN) | 2013-05-08 | — | — | EP | disclosed |
| CN-103096882-A | Transdermal preparation containing donepezil | NAL PHARMACEUTICALS LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20130095168-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL | NAL PHARMACEUTICAL GROUP LIMITED (HK) | 2013-04-18 | — | — | US | disclosed |
| US-8198335-B2 | Cosmetic material | PARAHERMOSA CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-2172185-B1 | Cosmetic material comprising octyl hydroxy stearate oligomer | PARAHERMOSA CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100087551-A1 | COSMETIC MATERIAL | PARAHERMOSA CO., LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2172185-A2 | Cosmetic material comprising octyl hydroxy stearate oligomer | Parahermosa Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191441-A1 | PROCESS FOR THE PREPARATION OF KARANJA OIL-BASED EPOXY AND ACYLOXY COMPOUNDS AS LUBRICANT BASESTOCKS | ELOVL3, ELOVL6, ELOVL1 | NAAA 3282/4885EPHX1 566/4885TSHR 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.